Our Current Trials

Condition	Trial Name	Sponsor
Solid	1403-0002: MDM2 Inhibitor BI 907828 and Anti PD-1 Antibody Ezabenlimab in Select Solid Tumors	Boehringer Ingelheim
Solid Tumors	1719-001: MRTX1719 in MTAP Deleted Advanced Solid Tumors	Mirati Therapeutics, Inc.
Rectal Cancer	19-288: Neoadjuvant TSR-042 (dostarlimab) for Patients with Rectal Adenocarcinoma	Memorial Sloan Kettering Cancer Center
Breast Cancer	ASCENT-03: Sacituzumab Govitecan as First Line Treatment for Patients With Triple Negative Breast Cancer	Gilead Sciences
Breast Cancer	ASCENT-04: Sacituzumab Govitecan in Combination With Pembrolizumab as First Line Treatment for Patients With PD-L1 Expressing Triple Negative Breast Cancer	Gilead Sciences
Cachexia in Colorectal or Pancreatic Cancer	AV-380-22-102: Study of GDF-15 Inhibitor AV-380 for the Treatment of Cachexia in Patients with Metastatic Colorectal or Pancreatic Cancer Receiving First Line Chemotherapy	AVEO Pharmaceuticals, Inc.
Solid Tumors	BI 1403-0001: MDM2 inhibitor BI 907828 in MDM2 Amplified Advanced Solid Tumors	Boehringer Ingelheim
Non-Small Cell Lung Cancer	BI 1479-0001: Anti-HER2 TKI BI 1810631 for the Treatment of HER2 Mutant NSCLC	Boehringer Ingelheim
Breast Cancer	BRI-ROL-001: SV-BR-1-GM Regimen in Combination With Retifanlimab in Patients With Metastatic or Locally Recurrent Breast Cancer Who Have Failed Standard Therapy	BriaCell Therapeutics Corporation
Dedifferentiated Liposarcoma	Brightline-1: MDM2 Inhibitor BI 907828 for the First Line Treatment of MDM2-Mutant Advanced or Metastatic Dedifferentiated Liposarcoma	Boehringer Ingelheim
Biliary Tract Cancer, Pancreatic Cancer	Brightline-2: MDM2 Inhibitor BI 907828 in MDM2 amplified, TP53 Wild Type Pancreatic or Biliary Tract Cancer	Boehringer Ingelheim
Breast Cancer	CDK2/4/6 Inhibitor RGT-419B in HR-Positive, HER2-Negative Metastatic Breast Cancer	Regor Pharmaceuticals, Inc.
Solid Tumor or Lymphoma	CS5001-101: A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas	CStone Pharmaceuticals
Solid Tumors	DAY101-102: Pan-RAF Inhibitor DAY101 for Patients with Relapsed/Refractory MAPK-Altered Solid Tumors	Day One Biopharmaceuticals, Inc.
Breast Cancer	DESTINY-Breast09: Trastuzumab deruxtecan for First Line Treatment of Advanced/Metastatic HER2-Positive Breast Cancer	AstraZeneca
Solid Tumors	ENV-ONC-101: Hedgehog Pathway Inhibitor in Patients with Advanced Solid Tumors Harboring PTCH1 Loss of Function MutationsTaladegib	Endeavor Biomedicines, Inc.
Central Nervous System Cancer	F8294-201b: BRAF Inhibitor FORE8394 in Recurrent/Refractory BRAF V600E Mutant CNS Malignancy	Fore Biotherapeutics
Solid Tumors	F8394-201a: BRAF Inhibitor FORE8394 for the Treatment of BRAF Fusion Positive Advanced Solid Tumors	Fore Biotherapeutics
Colon or Rectal Cancer	GO-010: Neoantigen Vaccine GRT-C901/GRT-R902 as Maintenance After First Line Metastatic Therapy	Gritstone bio, Inc.
Head and Neck Squamous Cell Carcinoma	GS-US-548-5916: Magrolimab Combinations in Recurrent or Metastatic HNSCC	Gilead Sciences, Inc.
Non-Small Cell Lung Cancer	HARMONIC: A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma	Lantern Pharma Inc.
Colon or Rectal Cancer	KRYSTAL-10: Adagrasib in KRAS G12C Mutated Colorectal Cancer	Mirati Therapeutics, Inc.
Solid Tumors	KRYSTAL-1: Multiple Cohort Study of Adagrasib Monotherapy or Combinations for Patients With KRAS G12C Mutant Solid Tumors	Mirati Therapeutics Inc.
Non-Small Cell Lung Cancer	KRYSTAL-7: Adagrasib Monotherapy or in Combination With Pembrolizumab as First Line Treatment for KRAS G12C Mutant NSCLC	Mirati Therapeutics Inc.
Diffuse Large B-Cell Lymphoma	LOTIS-9: Loncastuximab Tesirine and Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Patients	ADC Therapeutics SA
Colon or Rectal Cancer	LUT014 Gel for EGFR-Inhibitor Induced Acneiform Rash	Lutris Pharma Ltd.
Non-Hodgkin Lymphoma	MorningSun: Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies	Genentech, Inc.
Hyperkalemia/Chronic Kidney Disease	NYH-01: Hyperkalemia/Chronic Kidney Disease	Relypsa
Solid Tumors	OnTARGET: Crofelemer for Diarrhea Prophylaxis in Patients Receiving Targeted Therapy	Napo Pharmaceuticals
Colorectal Cancer	PORCUPINE: PORCN Inhibitor RXC004 Alone or in Combination with Nivolumab for Microsatellite Stable RNF43 or RSPO Altered Metastatic Colorectal Cancer	Redx Pharma Plc
Solid Tumors	PRECISION 1: Nab-Sirolimus for the Treatment of Patients With TSC1/2 Mutant Advanced or Metastatic Solid Tumor	Aadi Bioscience, Inc.
Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome	PRT1419-03: PRT1419 in Patients with Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or Myelodysplastic Syndrome	Prelude Therapeutics
Solid Tumors	REFOCUS: RLY-4408 in FGFR2-Altered Solid Tumors	Relay Therapeutics
Breast Cancer	SERENA-6: AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression	AstraZeneca
Solid Tumors	SPARTA: c-MET Inhibitor APL-101 for Patients with c-MET Altered Solid Tumors	Apollomics Inc.
Multiple Myeloma	TAK-573-2001: Modakafusp alfa in Combination with Daratumumab for the Treatment of Relapsed/Refractory Multiple Myeloma	Takeda Development Center Americas, Inc
Solid Tumors	TAPISTRY: Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You Platform Study	Hoffmann-La Roche
Breast Cancer	[Registry] Liquid vs Tissue Biopsy Concordance in Samples of 1st Suspected Breast Cancer Recurrence & Metastasis	Epic Sciences
Cancer Diagnosis	[Registry] MSK-IMPACT/ACCESS Genomic Profiling in Cancer Patients	Memorial Sloan Kettering Cancer Center
Various Indications	[Sample Collection] Clinical Biospecimen Procurement Protocol to Support Advancements in Medical Diagnoses of Diseases (PROMEDx)	Precision for Medicine
Solid Tumors	[Sample Collection] Collection and Distribution of Biofluids for Research Purposes	Bluestar Genomics
Solid Tumors	[Sample Collection] Detecting cancers Earlier Through Elective plasma-based Cancer SEEK Testing (DETECT-ASCEND 2)	Exact Sciences Thrive LLC
Various Indications	[Sample Collection] Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized Management of Patients (MTG-022)	MT Group
Various Indications	[Sample Collection] Prospective Collection of Samples for Research (SERATRIALS-05035)	SERATRIALS, LLC.
Solid Tumors	[Sample Collection] Vallania: A Case Control Study for the Development of Multiomics Blood Tests for Cancer Screening	Freenome Holdings Inc.
Solid Tumors	eNRGy: HER2xHER3 Bispecific Antibody MCLA-128 for the Treatment of an Advanced or Metastatic Solid Tumor Malignancy With a Documented NRG1 Fusion	Merus N.V.

Our Current Trials

Call Us

COVID-19 - Information